Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Net cash position, no leverage concern
Aptose Biosciences (APTOF) quality: score, margins and returns
Aptose Biosciences (APTOF) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Aptose Biosciences (APTOF) a high-quality business?+
Aptose Biosciences scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Aptose Biosciences's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from APTOF's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Aptose Biosciences scores well and where it falls behind.
SourceQuality score computed from the 10-Q filed 13 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with APTOF
Spot a number that looks wrong? Check it in APTOF's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing APTOF
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.